Alessandro Riva
M.D.

Alessandro Riva, M.D., is the chairman and CEO of Transgene, a biotechnology company developing immunotherapies for cancer, and he serves on the Boards of Directors of Century Therapeutics and BeiGene. Previously, he served as CEO of Intima Bioscience, CEO of Ichnos Sciences and executive vice president and global head of oncology therapeutics and cell and gene therapy of Gilead Sciences, where he led the company’s acquisition of Kite Pharma. Dr. Riva also was the executive vice president and global head of oncology development and medical affairs at Novartis Pharmaceuticals and was ad interim president of Novartis Oncology during the acquisition of GSK Oncology. He previously held roles at Farmitalia Carlo Erba, Rhône-Poulenc Rorer and Aventis, and he co-founded the Breast Cancer International Research Group and the Cancer International Research Group, where he served as CEO. Dr. Riva received his degree in medicine and surgery and a board certification in oncology and hematology from the University of Milan.